1 / 41

NEW INSIGHTS INTO PATHOGENESIS OF UIP/NSIP

NEW INSIGHTS INTO PATHOGENESIS OF UIP/NSIP. Dr. Derya Gumurdulu Cukurova University, Faculty of Medicine, Department of Pathology, Adana . Interstitial lung disease. Interstitial inflamation and/or fibrosis 30% etiology + 70% idiopathic Open lung biopsy

fabian
Download Presentation

NEW INSIGHTS INTO PATHOGENESIS OF UIP/NSIP

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. NEW INSIGHTS INTO PATHOGENESIS OF UIP/NSIP Dr. Derya Gumurdulu Cukurova University, Faculty of Medicine, Department of Pathology, Adana

  2. Interstitial lung disease • Interstitial inflamation and/or fibrosis • 30% etiology + • 70% idiopathic • Open lung biopsy • Communication between the pathologist and clinical and radiologic colleagues.

  3. Classification of idiopathic interstitial pneumonia *: American Thoracic Society/European Respiratory Society

  4. Usual interstitial pneumonia (UIP)/ (idiopathic pulmonary fibrosis) • 60% • 6 – 7. decade (mean 59 year-old) • Heterogeneus appearance (with alternating areas of normal lung, interstitial inflamation, fibrosis and honeycomb change) • Subpleural parenchyma most severely affected • Fibroblast foci • Honeycomb chnage (cystically dilated bronchioles)

  5. Usual interstitial pneumonia (UIP) (idiopathic pulmonary fibrosis) • Fibrosis and fibrotic scar • Mild interstitial inflamation • Tip 2 pneumocyte hiperplasia • Smooth muscle hyperplasia • Osseous metaplasia • Acute exacerbation (DAD or organizing pneumonia) • Visscher DW, Myers JL. Proc Am Thorac Soc 2006; 3: 322-329.

  6. Honeycomb change

  7. Fibroblast foci

  8. Desquamative interstitial pneumonia (DIP)/respiratory bronchiolitis interstitial lung disease (RBILD) • Highly related and some indistinguishable • DIP 8-17%, RBİAH 2% • Mean 44 year-old • Cigarette smoking • DİP much more uniform, RBİAH patchy and bronchiolocentric distribution • Pigmented alveolar macrophages, occasional multinucleated cells, eosinophils and lymphocytes within distal airspaces • İnflamatory infiltrates and mild fibrosis in alveolar septa

  9. DIP

  10. RBILD

  11. Diffuse alveolar damage (DAD) / Acute interstitial pneumonia (AIP) • Mean 55 year-old • Anologous ARDS, unknown etiology • Late or organizing DAD • Alveolar septa uniformly thickened, and distorted by proliferating fibroblast • Hyperplasia o alveolar lining cells, remnants of hyaline membranes, fibrin thrombi… • Honeycomb change at 3 or 4 weeks

  12. DAD

  13. Nonspesific interstitial pneumonia (NSİP) • 14-35 % • Mean 48 year-old • Idiopathic or connective tissue diseases, hipersensitivity pneumonia, drug-induced lung disease, chronic interstitial lung disease complicating DAD • Inflamation and/or fibrosis - uniform Visscher DW, Myers JL. Proc Am Thorac Soc 2006; 3: 322-329.

  14. NSIP • Cellular NSIP: Uniform alveolar septal infiltrate of mononuclear cells • Fibrotic NSIP: uniform collagen accumulation in alveolar septa, peribronchiolar interstitium, interlobular septa or visceral pleura

  15. Cellular NSIP

  16. Cellular and fibrotic NSIP

  17. Fibrotic NSIP

  18. Mean 55 year-old Patchy Polypoid plugs of loose organizing connective tissue in alveoli and/or bronchioli Mild interstitial inflamation Lung architecture is preserved. Organizing pneumonia (OP) / Cryptogenic organizing pneumonia (COP)

  19. Very rare Mean 50 year-old Diffuse interstitial lymphoid infiltration Predominantly T lymphocyte, plasma cells and histiocytes Peribronchiolar lymphoid aggregates (B lymphocyte) Lymphoid interstitial pneumonia (LIP)

  20. Pathogenesis of UIP/IPF • Inflammation (alveolitis) Hypothesis (1984) • Neutrophil accumulation • It is a consequence and not a cause of UIP/IPF (in advaced stage, due to the extensive tissue remodeling and traction bronchiectasis) Crystal RW. et al. N Engl J Med 1984; 310: 235-244. Noble PW. et. al., Am J Respir Cell Mol Biol 2005; 33: 113-120.

  21. Multiple hit hypothesis • This hypothesis based on the idea that injury/inflammation of the alveolar-capillary constituents and basement membrane leads to type I epithelial and endothelial cells, the proliferation of type II cells, the loss of alveolar space integrity, the recruitment and proliferation of stromal cells and the deposition of the ECM.

  22. The cycle of dysregulated repair involving an initial injury or inflammatory event is purported to lead to the perpetuation of chronic inflammation, with deposition of the ECM progressing inevitably to end-stage pulmonary fibrosis. Strieter RM. Chest 2005; 128: 526S-532S. Noble PW, Homer RJ. Clin Chest Med 2004; 25: 749-758. White ES, et al. J Pathol 2003; 201: 343-354.

  23. Apoptosis and proliferation Tip II cells apoptosis and injury • Pro-apoptotic protein (fas-fas ligand) and oxidative stress • TNF  • TGF- • Angiotensin II

  24. Loss of basament membrane integrityFrustrated epithelial cell generation

  25. Growth factors • Keratinocyte growth factor (KGF), • TGF-, • TGF- , • Insulin-like growth factor-1 (ILGF-1), • Platelet-derived growth factor (PDGF), • Fibroblast growth factor-2 • Hepatocyte growth factor GF activate tyrosine kinase signaling pathways • Fibroblast proliferation and matrix production • Activation of wnt/ catenin signaling pathway

  26. Plasminogen activation system • Critical to normal wound healing • Plasminogen activated by tPA or uPA to plasmin • Plasmin responsible for degrading fibrin clots and allowing for wound reepithelialization. • Inhibits by plasminogen activator inhibitors (PAI). • Overexpression of PAIs promotes fibrosis in IPF

  27. Angiogenesis and angiostasis • Angiogenic activite • Imbalance of pro-angiogenic chemokines (IL-8 ve ENA-78) and anti-angiogenic CXC chemokines (interstitial pneumonia-10-IP-10) • VEGF • Enhanced angiogenesis in earlier stage • Loss of blood vessels in advanced stage

  28. Ekstracellular matrix production and degradation • Imbalance of matrix production and degradation • TGF- promote matrix production and inhibit TIMP (Tissue inhibitor metalloproteinase) • Degradation products inflammation and fibrosis • Metalloproteinase could lead to basament membrane destruction

  29. Profibrotic Th2 cytokines • IL-4, IL-5, IL-13 • The link between Th2 cytokines and fibrosis has been established in animal models. • Directing therapies to restore the balance of Th1 and Th2 cytokines is not an unreasonable approach

  30. Fibroblast and myofibroblast • Origin: resident cells ?, epithelial cells to transition to a mesenchymal phenotype ? • IPF fibroblasts have different properties than normal lung fibroblast • Bone marrow-derived precursors can contribute to the fibroblast pool after lung injury

  31. In fibroblastic foci The production of new collagen and fibronectin Contractile properties (SMA +) In normal wound healing, appear transiently Normal fibroblasts differentiate into myofibroblasts in vivo ? Myofibroblast

  32. Myofibroblast • TGF  induce the expression of SMA in normal lung fibroblasts • TGF  inhibits apoptosis of myofibroblast • UIP myofibroblasts persist

  33. Abnormality in host defense • The host factors that limit the extent of fibrosis • Defects in endogeneus mechanism • PG E2 have antifibrotic properties • Fibroblasts from patients of IPF have been shown to have diminished capacity to produce PG E2 • Herpesvirus DNA is detected. Epithelial injury could occur in response to such viral infections.

  34. Summary • IPF is a complex disorder • Many pathogenic events have been observed • Currently, no unifying hypothesis explains all the abnormalities • The inciting event for lung injury is unknown • Although more questions than answers currently exist, great strides are being made in elucidating new mechanisms in pathogenesis • Future therapeutic approaches likely will target several pathways simultaneously with combinations of interventions

  35. Thank you

More Related